Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness

BACKGROUND: Vedolizumab (VDZ) is a humanized monoclonal IgG1 antibody which inhibits leukocyte vascular adhesion and migration into the gastrointestinal tract through α4β7 integrin blockade. AIMS: We retrospectively assessed the 12-month, real-world efficacy and safety of VDZ as induction and mainte...

Descripción completa

Detalles Bibliográficos
Autores principales: Zezos, Petros, Kabakchiev, Boyko, Weizman, Adam V, Nguyen, Geoffrey C, Narula, Neeraj, Croitoru, Kenneth, Steinhart, A Hillary, Silverberg, Mark S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165264/
https://www.ncbi.nlm.nih.gov/pubmed/32328546
http://dx.doi.org/10.1093/jcag/gwy065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165264/
https://www.ncbi.nlm.nih.gov/pubmed/32328546
http://dx.doi.org/10.1093/jcag/gwy065

Ejemplares similares